Physician profile
Michelle C Springer
NPI 1235367525
$13,642.81
in general payments reported to CMS, 2019-2025
40 companies · $3,402 in 2025
The $3,402 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $1,063 · 2021: $1,525 · 2022: $1,912 · 2023: $1,745 · 2024: $2,166 · 2025: $3,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,280 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,280.18 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,807.47 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,367.01 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,151.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $908.49 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $591.86 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $572.63 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $555.02 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $433.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $397.47 | 2019-2024 | Linzess |
| Ardelyx, INC. | $328.98 | 2023-2025 | Ibsrela |
| Celgene Corporation | $293.36 | 2021-2024 | Zeposia |
| Genzyme Corporation | $279.62 | 2022-2025 | |
| Ucb, INC. | $248.52 | 2019-2020 | |
| Daiichi Sankyo INC. | $229.98 | 2019-2025 | Injectafer |
| Lilly USA, LLC | $226.69 | 2024-2025 | Omvoh |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.